Sutro Biopharma (STRO) Cash from Investing Activities (2017 - 2025)

Sutro Biopharma has reported Cash from Investing Activities for 9 years, with the latest figure at $18.7 million in Q4 2025.

• Quarterly Cash from Investing Activities fell 78.62% year-over-year to $18.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $45.0 million (down 79.4% YoY) and the FY2025 annual result came in at $45.0 million, down 79.4% from the prior year.
• Cash from Investing Activities fell to $18.7 million in Q4 2025 per STRO's latest filing, from $40.0 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $147.3 million in Q3 2024 and troughed at -$121.7 million in Q1 2021.
• A 5-year average of $6.4 million and a median of $12.3 million in 2021 frame the typical range for Cash from Investing Activities.
• The widest YoY moves for Cash from Investing Activities: up 715.44% in 2022, down 3380.69% in 2022.
• Over 5 years, Cash from Investing Activities stood at $20.8 million in 2021, then slumped by 282.29% to -$37.9 million in 2022, then jumped by 37.93% to -$23.5 million in 2023, then jumped by 472.08% to $87.5 million in 2024, then slumped by 78.62% to $18.7 million in 2025.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $18.7 million, $40.0 million, and $2.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.